Immuneering Taps Ex-Terns CFO Gengos After $6.7B Merck Acquisition
IMRX•Immuneering has appointed Andrew Gengos as CFO effective July 16, 2026, leveraging his 25-year leadership in biotech finance and corporate development. Gengos drove Terns Pharmaceuticals through its $6.7 billion Merck acquisition and will oversee financial strategy, capital allocation and investor relations as atebimetinib progresses in Phase 3.
1. Appointment Details
Immuneering announced that Andrew Gengos will assume the role of Chief Financial Officer on July 16, 2026. In this capacity, he will report to the CEO and join the executive team as the company advances its oncology pipeline.
2. CFO Background
Gengos brings over 25 years of biotech finance and corporate development experience, most recently serving as CFO and Head of Corporate Development at Terns Pharmaceuticals during its $6.7 billion acquisition by Merck. His prior roles include CFO at Athira Pharma, business leadership at Cyteir Therapeutics, and corporate strategy at Amgen.
3. Strategic Implications
As CFO, Gengos will lead financial strategy, capital allocation, investor relations, business development and corporate development activities. His appointment is intended to bolster funding and strategic partnerships as Immuneering’s lead candidate, atebimetinib, advances through a global pivotal Phase 3 trial.
